Saniona AB (SE:SANION)
:SANION
Want to see SE:SANION full AI Analyst Report?
SANION Stock Chart & Stats
kr21.10
-kr0.15(-2.06%)
At close: 4:00 PM EST
kr21.10
-kr0.15(-2.06%)
Day’s Range― - ―
52-Week Rangekr7.91 - kr28.30
Previous CloseN/A
Volume191.43K
Average Volume (3M)1.06M
Market Cap
kr1.88B
Enterprise Valuekr1.27B
Total Cash (Recent Filing)kr580.82M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.11
Next Earnings
May 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.09
Shares Outstanding138,030,140
10 Day Avg. Volume913,988
30 Day Avg. Volume1,064,614
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)4.30
Price to Sales (P/S)6.29
P/FCF Ratio13.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr11.00M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetReporting zero total debt in 2025 materially improves financial flexibility for a biotech developer. It reduces fixed interest obligations, lowers refinancing risk, and gives management optionality to fund R&D, partnerships or M&A from equity/cash without near-term debt pressure.
Positive Cash GenerationSustained positive operating and free cash flow across 2024–2025 signals the company can generate internal funding for operations and development. For a small biotech this reduces reliance on dilutive financing and supports multi-quarter program funding and partnership negotiations.
Profitability TurnaroundA return to strong net income after multi-year losses indicates structural improvement in cost base or revenue quality. Durable profitability enhances reinvestment capacity, strengthens negotiating leverage with partners, and improves the company's ability to sustain development programs without constant capital raises.
Bears Say
Revenue VolatilityLarge swings in revenue across consecutive years point to reliance on lumpy milestone, licensing or partner payments or concentration in few programs. This weakens revenue predictability, complicates budgeting for R&D and commercial planning, and raises execution risk over the next several quarters.
Sharp Free Cash Flow DeclineA 64.8% drop in free cash flow despite positive FCF in prior years highlights operational sensitivity and timing effects. Such volatility can quickly erode runway, force opportunistic financing, or delay program milestones, creating structural funding risk even with a recent positive cash profile.
Historical Capital InstabilityA history of negative equity and previously strained leverage suggests the firm's capital structure has been unstable. Even with recent improvement, prior instability can indicate recurring funding needs, higher perceived risk by partners and investors, and a less-proven track record of sustaining balance-sheet strength.
Saniona AB News
SANION FAQ
What was Saniona AB’s price range in the past 12 months?
Saniona AB lowest stock price was kr7.91 and its highest was kr28.30 in the past 12 months.
What is Saniona AB’s market cap?
Saniona AB’s market cap is kr1.88B.
When is Saniona AB’s upcoming earnings report date?
Saniona AB’s upcoming earnings report date is May 26, 2026 which is in 3 days.
How were Saniona AB’s earnings last quarter?
Saniona AB released its earnings results on Feb 26, 2026. The company reported -kr0.302 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.302.
Is Saniona AB overvalued?
According to Wall Street analysts Saniona AB’s price is currently Overvalued.
Does Saniona AB pay dividends?
Saniona AB does not currently pay dividends.
What is Saniona AB’s EPS estimate?
Saniona AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Saniona AB have?
Saniona AB has 138,030,140 shares outstanding.
What happened to Saniona AB’s price movement after its last earnings report?
Saniona AB reported an EPS of -kr0.302 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -14.498%.
Which hedge fund is a major shareholder of Saniona AB?
Currently, no hedge funds are holding shares in SE:SANION
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Saniona AB
Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders. The company has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.
Technical Analysis
Oncopeptides AB
―
SynAct Pharma AB
―
Xbrane Biopharma AB
―
Xspray Pharma AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---